BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Sanofi Pharma Bristol-Myers Squibb SNC submitted on 6 September 2006 an 
application for Marketing Authorisation to the European Medicines Agency (EMEA) for Irbesartan 
Winthrop, through the centralised procedure according to Regulation (EC) No 726/2004. 
The legal basis for this application refers to Article 10c of Directive 2001/83/EC, as amended relating 
to informed consent from the marketing authorisation holder, Sanofi Pharma Bristol-Myers Squibb 
SNC, for the authorised medicinal product APROVEL (EU/1/97/046/001-0033). 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
The initial product, APROVEL, has been given a Community Marketing Authorisation on 27 August 
1997.  
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur: Concepción Prieto Yerro 
Co-Rapporteur: Pirjo Laitinen-Parkkonen 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 6 September 2006  
The procedure started on 27 September 2006.  
The Rapporteur's first Assessment Report was circulated to all CHMP members on 16 October 
2006. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on  
13 October.  
The Rapporteur circulated an updated Assessment Report to all CHMP members on  
13 November 2006. 
During the meeting on 13-16 November 2006, the CHMP, in the light of the overall data 
submitted and the scientific discussion within the Committee, issued a positive opinion for 
granting a Marketing Authorisation to Irbesartan WINTHROP on 16 November 2006. The 
applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-
authorisation on 14 November 2006.  
The CHMP opinions were forwarded, in all official languages of the European Union, to the 
European Commission, which adopted the corresponding Decisions on 19 January 2007. 
 
 
 
 
 
 
 
 
 
 
 
 
